

Glioma Club

Friday, 3rd October 2025

Mary Ward House, 7 Tavistock Place, London WC1H 9SN

9.00 Registration and refreshments

09.30 Introduction and welcome – Profs Simona Parrinello and Silvia Marino

Session 1

Chair: Prof. Silvia Marino, QMUL

- 09.35 Dr Lucy Brooks, University of Oxford
Cell-state-mediated therapy resistance in glioblastoma
- 10.05 Dr Vincenzo D'Angiolella, University of Edinburgh
Ubiquitin system in the pathogenesis of brain cancers: drivers and therapeutic opportunities
- 10.35 Dr Zeyu Wang, University of Edinburgh – Junior Forum
SOX9 constrains glioblastoma stem cell progression by blocking cells' interaction with the extracellular matrix
- 10.50 Zan Florjanic Baronik, UCL Cancer Institute – Junior forum
Axonal injury is a targetable driver of glioblastoma progression

11.05 Coffee Break

Session 2

Chair: Prof Simona Parrinello

- 11.35 **Keynote**
Dr Peter Dirks, University of Toronto, The Hospital of Sick Children, Canada
- 12.25 Patricia Rojas-Sanchez, Manchester University – Junior forum
Non-Invasive Detection and Monitoring of Glioblastoma Subtypes via Dual-Marker Plasma Proteomics
- 12.40 Alsadeg Bilal, University of Edinburgh – Junior forum
Using live human brain slice cultures to interrogate myeloid:GSC interactions

12.55 Lunch and Network

Session 3

Chair: Dr Vincenzo D'Angiolella

- 14.00 Dr Matt Loose, University of Nottingham
Rapid Intraoperative Diagnostics for CNS Tumours
- 14.30 Dr Ola Rominiyi, University of Sheffield
Exploring DNA repair differences across surgical scales to treat residual glioblastoma
- 15.00 Dr Qianqian Zhang, Sanger Centre – Junior forum
Transcriptional profiling identifies functional niche-specific TAMs subtypes that support Glioblastoma

- 15.15 Jiali Liu, UCL Cancer Institute – Junior forum
Targeting IL-2 Signalling with highly selective IL-2R agonists in Glioblastoma Enhances Immune Effector Cell Response in Mouse and Patient-derived Models
- 15.30 Thomas Willott, Queen Mary University of London – Junior forum
Modelling medulloblastoma initiation in human cerebellar organoids

15.45 Refreshments

Session 4

Chair: Dr Steve Pollard

- 16.15 **Keynote**
Dr Valerie Weaver, University of California San Francisco
Force reprograms anti-tumour immunity to drive malignancy and compromise treatment response
- 17.05 **Closing remarks – Junior Forum prizes**

17.15 Reception and refreshments

This Symposium is sponsored by the Edinburgh–UCL CRUK Glioma Centre of Excellence